GlassScriptPhysician profile
Daniel J Molloy
NPI 1215255781
$13,496.21
in general payments reported to CMS, 2019-2025
54 companies · $2,710 in 2025
The $2,710 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,675 · 2020: $1,433 · 2021: $1,551 · 2022: $1,499 · 2023: $2,093 · 2024: $2,535 · 2025: $2,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,275 · Education: $62.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,275.13 |
| Education | $62.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,584.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,363.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,331.09 | 2019-2025 | |
| Lilly USA, LLC | $1,193.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,023.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $806.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $638.53 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $622.35 | 2019-2025 | |
| Indivior INC. | $484.39 | 2019-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $366.85 | 2022-2025 | |
| Orexo US, INC. | $366.22 | 2019-2024 | Zubsolv |
| Novartis Pharmaceuticals Corporation | $237.88 | 2019-2024 | |
| Corcept Therapeutics | $232.02 | 2024-2025 | Korlym |
| Shield Therapeutics INC | $217.04 | 2023-2025 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $215.74 | 2021-2025 | Eliquis, Camzyos |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $215.69 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.08 | 2019-2024 | Relistor |
| Phathom Pharmaceuticals, INC. | $204.98 | 2023-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $198.96 | 2024-2025 | Rexulti |
| Amgen INC. | $170.06 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $162.29 | 2019-2023 | Belsomra, Januvia, Steglatro |
| Alkermes, INC. | $153.91 | 2019-2024 | Vivitrol, Vivitrol |
| Astellas Pharma US INC | $137.51 | 2024-2025 | Veozah |
| Mdd US Operations, LLC | $130.83 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $128.84 | 2019-2024 | |
| Mylan Specialty L.P. | $114.47 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $109.40 | 2019-2021 | |
| Harmony Biosciences LLC | $81.53 | 2022-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $81.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.26 | 2020 | |
| Verona Pharma, INC. | $62.52 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $52.28 | 2022-2023 | Seglentis, Livalo |
| Dexcom, INC. | $49.08 | 2021-2025 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $42.98 | 2021 | |
| Hikma Pharmaceuticals USA | $42.00 | 2023 | Kloxxado |
| Abbott Laboratories | $40.56 | 2022-2025 | Freestyle Libre 3 |
| Pharmacosmos Therapeutics INC. | $36.61 | 2025 | Monoferric |
| Axsome Therapeutics, INC. | $35.81 | 2025 | Auvelity |
| Allergan, INC. | $22.92 | 2020 | |
| Sun Pharmaceutical Industries INC. | $22.79 | 2020 | |
| Sumitomo Pharma America, INC. | $21.66 | 2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $19.95 | 2022 | |
| Uswm, LLC | $19.19 | 2021 | |
| Advanced Oxygen Therapy INC. | $18.67 | 2023 | Topical Oxygen Chamber For Extremities |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2022 | |
| Valeritas, INC. | $17.84 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.76 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.52 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.10 | 2025 | Caplyta |
| Viatris Specialty LLC | $15.06 | 2025 | Yupelri |
| Tandem Diabetes Care, INC. | $14.60 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Sentynl Therapeutics, INC. | $13.93 | 2019 | |
| Hologic Sales and Service, LLC | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Molloy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.